BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choy H, Schwartzberg LS, Dakhil SR, Garon EB, Gerber DE, Choksi JK, Govindan R, Peng G, Koustenis A, Treat J. Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol. 2013;8:1308-1316. [PMID: 23981966 DOI: 10.1097/jto.0b013e3182a02546] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017; 8(1): 1-20 [PMID: 28246582 DOI: 10.5306/wjco.v8.i1.1] [Cited by in CrossRef: 102] [Cited by in F6Publishing: 95] [Article Influence: 20.4] [Reference Citation Analysis]
2 Wauters E, Vansteenkiste J. Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients? J Thorac Dis 2014;6:574-7. [PMID: 24976973 DOI: 10.3978/j.issn.2072-1439.2014.05.16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Gadgeel SM. The optimal chemotherapy for stage III non-small cell lung cancer patients. Curr Oncol Rep 2011;13:272-9. [PMID: 21479993 DOI: 10.1007/s11912-011-0170-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
4 Liu T, He Z, Dang J, Li G. Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis. Radiat Oncol 2019;14:55. [PMID: 30925881 DOI: 10.1186/s13014-019-1239-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Stinchcombe TE, Bogart JA. Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Oncologist. 2012;17:682-693. [PMID: 22531360 DOI: 10.1634/theoncologist.2012-0020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
6 Nieder C. [Chemo- versus radiochemotherapy in stage III non-small-cell lung cancer with poor prognosis: the Conrad Study]. Strahlenther Onkol 2014;190:109-10. [PMID: 24253183 DOI: 10.1007/s00066-013-0490-3] [Reference Citation Analysis]
7 Zhao Q, Wang Z, Huang W, Wang Q, Yu S, Zhou T, Han D, Wu Z, Gong H, Sun H, Zhang J, Wei Y, Li H, Zhang Z, Lin H, Li B. Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer. Oncotarget 2016;7:8422-31. [PMID: 26761213 DOI: 10.18632/oncotarget.6871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]